Bobak Azamian
2023
In 2023, Bobak Azamian earned a total compensation of $3.1M as President, Chief Executive Officer and Board Chairman at Tarsus Pharmaceuticals, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $450,300 |
|---|---|
| Option Awards | $1,017,968 |
| Salary | $619,500 |
| Stock Awards | $1,029,364 |
| Other | $13,200 |
| Total | $3,130,332 |
Azamian received $1M in stock awards, accounting for 33% of the total pay in 2023.
Azamian also received $450.3K in non-equity incentive plan, $1M in option awards, $619.5K in salary and $13.2K in other compensation.
Rankings
In 2023, Bobak Azamian's compensation ranked 286th out of 3,006 executives tracked by ExecPay. In other words, Azamian earned more than 90.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 286 out of 3,006 | 91st |
Division Manufacturing | 156 out of 1,650 | 91st |
Major group Chemicals And Allied Products | 105 out of 918 | 89th |
Industry group Drugs | 102 out of 881 | 88th |
Industry Biological Products, Except Diagnostic Substances | 35 out of 213 | 84th |
Source: SEC filing on April 26, 2024.
Azamian's colleagues
We found three more compensation records of executives who worked with Bobak Azamian at Tarsus Pharmaceuticals in 2023.